Lung Cancer Clinical Trial
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Summary
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria:
Patients with a diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists.
Patient has a good performance status (ECOG 0 or 1).
Exclusion Criteria:
Prior treatment with either pemetrexed or SU011248.
Coughing up blood within 4 weeks before starting study treatment (small amounts okay).
Hypertension that cannot be controlled by medications.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Aurora Colorado, 80045, United States
Ottawa Ontario, K1H 8, Canada
Montreal Quebec, H2L 4, Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.